<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00597532</url>
  </required_header>
  <id_info>
    <org_study_id>02-062</org_study_id>
    <nct_id>NCT00597532</nct_id>
  </id_info>
  <brief_title>Effect of Soy Supplementation on Cellular Markers in Normal and Cancerous Breast Tissue: A Randomized Placebo Controlled Study</brief_title>
  <official_title>Effect of Soy Supplementation on Cellular Markers in Normal and Cancerous Breast Tissue: A Randomized Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      To Test Effect of Soy Supplementation on Cellular Markers in Normal and Cancerous Breast&#xD;
      Tissue using a Randomized Placebo Controlled Study.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        -  To determine (by immunohistochemistry) whether specific cellular markers and gene&#xD;
           products associated with breast carcinoma can be altered by soy therapy.&#xD;
&#xD;
        -  To identify genes that can be altered by soy therapy in normal and neoplastic breast&#xD;
           tissues by unbiased gene expression analysis using microarrays.&#xD;
&#xD;
        -  To compare specific cellular markers and pathways (immunohistochemistry), and gene&#xD;
           expression using microarrays in normal and cancerous breast tissue.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient Population:&#xD;
&#xD;
      Pre and post menopausal women with breast cancer diagnosed by core needle biopsy scheduled to&#xD;
      undergo breast cancer resection for an invasive carcinoma.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        -  To determine (by immunohistochemistry) whether specific cellular markers and gene&#xD;
           products associated with breast carcinoma can be altered by soy therapy.&#xD;
&#xD;
        -  To identify genes that can be altered by soy therapy in normal and neoplastic breast&#xD;
           tissues by unbiased gene expression analysis using microarrays.&#xD;
&#xD;
        -  To compare specific cellular markers and pathways (immunohistochemistry), and gene&#xD;
           expression using microarrays in normal and cancerous breast tissue.&#xD;
&#xD;
      Study Design and Intervention Plan:&#xD;
&#xD;
        -  Eligible patients will be consented at the time of visit with MSKCC breast surgeon and&#xD;
           randomized to receive soy (soy protein supplementation 50 grams/day), or placebo (milk&#xD;
           protein supplementation 50 grams/day) over the period until their surgery.&#xD;
&#xD;
        -  The diagnostic biopsy (already available at time of appointment with MSKCC surgeon) will&#xD;
           be analyzed by immunohistochemistry for proliferation (Ki67) and apoptosis (TUNEL).&#xD;
           Additional immunohistochemistry will include HER2, TP53, cyclin D1, p27, BCL2, ER and&#xD;
           PR.&#xD;
&#xD;
        -  Excision of the breast carcinoma (lumpectomy or mastectomy) will proceed in standard&#xD;
           fashion.&#xD;
&#xD;
        -  The post-therapy excision specimen will be processed in a standard fashion. Pathologic&#xD;
           features, margin status, and tumor size will be assessed by a light microscopic&#xD;
           examination of histological sections. In addition to this routine processing,&#xD;
           immunohistochemistry assays for proliferation (Ki67), apoptosis (TUNEL), HER2, TP53,&#xD;
           cyclin D1, p27, BCL2, ER, and PR will be performed. For correlative biological studies&#xD;
           pathologists will select approximately .5 cubic mm representative sections of the&#xD;
           neoplastic tissues and normal adjacent breast tissue, which will be snap frozen for gene&#xD;
           expression analysis using microarrays.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome of the study is comparison of the change in proliferation (Ki67) and apoptosis (TUNEL) in cancerous tissue between the 2 groups.</measure>
    <time_frame>Conclusion of the study</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>soy (soy protein supplementation 50 grams/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>milk protein supplementation 50 grams/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Soy</intervention_name>
    <description>soy (soy protein supplementation 50 grams/day)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Milk</intervention_name>
    <description>placebo (milk protein supplementation 50 grams/day)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent obtained&#xD;
&#xD;
          -  Breast mass &gt; .5 cm (determined by mammogram, ultrasound, MRI, or palpable criteria)&#xD;
&#xD;
          -  Core biopsy diagnosis of invasive carcinoma of the breast&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of active malignancy within previous two years (except for non-melanoma skin&#xD;
             cancer and history of breast cancer).&#xD;
&#xD;
          -  Regular soy consumption (consumption of more than 3 serving of soy or soy&#xD;
             products/supplements per week)&#xD;
&#xD;
          -  Allergy to soy or milk protein&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moshe Shike, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>January 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2008</study_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Soy</keyword>
  <keyword>Milk</keyword>
  <keyword>Supplementation</keyword>
  <keyword>02-062</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

